“Serum Markers Predicting Early Non-Responsiveness to Infliximab in Rheumatoid Arthritis: Tumor Necrosis Factor (TNF)-Alpha, TNFRII, and Interleukin (IL)-17 As Potential Indicators” (2025) Iraqi Journal of Medical Sciences, 23(1). doi:10.22578/qchesh02.